BioMarin take out speculation resurfaces

Orphan drug company BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is once again the subject of takeout rumors. According to a story in The Independent, AstraZeneca plc (LSE:AZN; NYSE:AZN) and Roche (SIX:ROG; OTCQX:RHHBY) are considering making a bid for BioMarin, along with fellow Orphan drug company Shire plc (LSE:SHP; NASDAQ:SHPG). Shire and Roche declined to comment, while BioMarin and AstraZeneca could not be reached. In September, Roche denied rumors it was raising debt in preparation for making a bid to acquire the biotech (see BioCentury Extra, Sept. 19). ...